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Overdose antidote naloxone takes harm-reduction centre stage
Every nation in the United Kingdom saw increased drug misuse deaths between 2013 or 2014 and 2015. In
raw numbers, in proportion to the general population, and probably too in proportion to the number of
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to 2,683 or 81% of the
total. Public Health
England’s 2015 report
to the European drug
misuse agency says 88% of drug poisoning deaths which actually happened in 2013 involved opioids, a
proportion which has remained broadly similar since 2004.
What caused the upturns was a major talking point in 2016. Especially in England, commentators targeted
the UK government’s recovery agenda for failing to maintain harm-reduction services and a harm-reduction
ethos. Others emphasised the aging of the heroin-using population as fewer young people join their ranks,
leaving the overall population increasingly dominated by older and more multiply ill and vulnerable users
who started using decades ago, a trend only briefly interrupted by the ‘heroin drought’ of (roughly) 2010 to
2012. Investment in treatment in England and national naloxone programmes in Scotland, Wales and
Northern Ireland, did not prevent the upturns, but almost certainly moderated their steepness.
Whatever the causes, in terms of remedies the figures set the stage for naloxone – an antidote which
specifically targets overdoses involving opiate-type drugs – to become the main new hope for curbing the
rise in drug overdose deaths. Further forefronting naloxone is the 2016 revision to the Public Health
Outcomes Framework for England – indicators of the nation’s health by which local areas are held to
account. A sign of national concern, the revision added the rate of drug misuse deaths per million of an
area’s population to the indicators. According to the Department of Health, it was a response to “a rising
trend in drug related deaths over the last few years”. One relatively inexpensive way to directly target drug
misuse deaths is for local areas to mount naloxone distribution campaigns.
While this hot topic focuses on naloxone, another has explored the overdose figures and overdose
prevention though means other than naloxone programmes. To help absorb the messages, most sections
below start with one or two introductory paragraphs which convey the essence of what follows. These
paragraphs end in    more ...
National naloxone programmes across the UK – but not in England
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The naloxone kit approved for use in the UK
Naloxone is a drug which rapidly reverses the effects of opiate-type drugs, including the respiratory
depression which causes overdose. It became the main new hope for curbing the death rate after in
2005 UK law was amended to permit emergency administration by any member of the public. The
drugs naloxone reverses are not the sole cause of overdose deaths – benzodiazepines and alcohol
play a big role – but across the UK, 88% of drug poisoning deaths in 2013 involved opiate-type
drugs. Naloxone distribution has been aided by a medically approved kit and a relaxation of
prescription-only requirements. Of all the UK nations, England has yet to take advantage of these
developments to mount a coordinated national programme, but has contributed to the UK research
base helping to validate naloxone programmes    more ....
In May 2013 the naloxone ‘kit’ Prenoxad became
approved in the UK for use in opioid overdose
emergencies by non-medical personnel. The kit
includes a pre-filled syringe, product instructions, and
relevant first aid guidelines. Approval was seen as an
important step to widening availability. It meant GPs
could prescribe kits to suitably trained drug users and
with their permission to their associates and families.
Patient group directions also enable doctors to
authorise pharmacists and nurses to supply the kits.
Creating an exception to the need for a prescription,
from October 2015 drug services in England and Wales
were permitted without prescription to order supplies
of naloxone and distribute these to drug users at risk of overdose or to people likely to be in contact
with them, such as families, carers or hostel staff. Apart from this important exception, naloxone
supply remains restricted by the prescription-only status which in 2012 the UK’s Advisory Council on
the Misuse of Drugs wanted reviewed, after concluding that wider provision of naloxone could result
in a reduction in drug-related deaths in the UK. In 2016 the Council acknowledged that so long as
the only preparation approved in the UK is injectable, over-the-counter sales are unlikely to be
allowed, but might be permitted for a version sprayed up the nose. Whatever it takes, the Council’s
view was that widespread, easy and inexpensive access to naloxone is an important overdose
prevention tactic.
Though more might be done in other UK nations, England has felt the brunt of criticism for not
grabbing the opportunity offered by naloxone to reduce the death rate. Unlike other UK nations, in
the name of localism England has so far not established a centrally driven national programme, a
point made in a parliamentary question backed by 21 MPs tabled at the end of October 2014. Some
local administrations are attempting to make naloxone available to all at-risk individuals, but from
one such area came criticism that “coverage across England remains sparse”. Towards the end of
2014, the relative inaction in England and the recent increase in deaths there prompted the
formation of the Naloxone Action Group “to push the agenda”.
Institutions in England can, however, take credit for grabbing the opportunity to validate naloxone
through research in the UK context. The first large-scale UK follow-up study of naloxone-based
overdose prevention training took place in England, and the results were published in 2008. It found
these programmes can successfully be delivered to drug users in treatment, resulting in
substantially improved knowledge and competence. Though only a few times, naloxone was used to
save lives even within the study’s three-month follow-up period. The first UK randomised trial also
ended up being conducted in England. The aim was test prison-release naloxone by randomly
allocating prisoners with a history of heroin use to be supplied a naloxone kit before release, versus
a similar package not containing a naloxone kit. The researchers realised this methodology was
inappropriate when they discovered that released prisoners were three times more likely to use
their kit to save someone else rather than use it or have it used to save them. This meant it was
unrealistic to expect the overdose death rate to be significantly lower among prisoners given the
kits. Nevertheless, the trial produced evidence that lives might have been saved by issuing the kits.
Of 112 prisoners who completed follow-up surveys when reimprisoned within six months, 21% said
they had administered naloxone to themselves or another person before the arrival of a doctor or
ambulance, versus just 9% of prisoners not issued kits.
While this and other evaluations of naloxone kit distribution programmes focus on how often the
naloxone was used, the associated training gives trainees the skills and information they need to
save lives without naloxone, a frequent occurrence which alleviates one of the main limitations of
the schemes – kits not being available at the time and place of an overdose. In these situations,
naloxone programmes may still have helped save lives, even though no administration of drug has
been recorded.
Evaluations of national UK programmes
Its record in reducing opioid overdose deaths shortly after release from prison is evidence of the
effectiveness of Scotland’s naloxone programme, but one yet to be matched by evidence of
effectiveness in other circumstances. Especially since the upturns in during-year drug misuse deaths
in 2014 and those registered in 2015, it is unclear too whether Wales’s national naloxone
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As the number of naloxone kits issued in prison
increased, post-prison deaths accounted for a
diminishing % of all opioid-related deaths in
Scotland.
programme has helped reduce deaths. However, naloxone kits have been used many
hundreds of times. Together with training thousands of drug users and their contacts in other
lifesaving techniques, it seems inconceivable that lives have not been saved, even if this is
difficult to prove to scientific standards  more ...
Scotland
Launched in 2011, Scotland’s national naloxone programme has been gathering pace, outside
prison distributing 6,498 ‘take home’ naloxone kits in 2014/15 compared to 5,395 the year
before, 3,132 in 2012/13, and 2,743 in 2011/12. In 2014/15 another 878 kits were issued to
drug users leaving prison, down from a peak of 1,077 the year before. Reasons given for
trainees being given a replacement kit indicated that in 2014/15 kits issued outside prison
had been used 644 times, up from 424 times the year before and 212 and 132 in the first
two years of the programme. An unknown extra number will have been used without the
carrier returning for another kit.
An extremely high-risk period for former opiate users, in Scotland the proportion of opioid-
related deaths occurring within four weeks of release from prison had been identified as the
key indicator of success of a programme which had specifically and systematically targeted
prisons. This was made the main metric in a study which compared opioid-related death rates
in the five years before the programme’s implementation (2006–10) with those during its
first three years (2011–13). A secondary indicator of success added in the proportion which
occurred during the corresponding period after discharge from hospital, another high-risk
period.
The post-prison period accounted for 9.8%
of opioid-related deaths before the
programme but 6.3% after, a 36%
reduction taken as indicative of a lifesaving
impact  chart. Also reduced was the
combined total of post-prison and
post-hospital deaths as a proportion of the
total. Routinely collected statistics
indicated that the trend down in the
proportion of opioid-related deaths
occurring shortly after release from prison
continued into 2014, when the figure was
3.1%, having steadily decreased since the
start of the national naloxone programme.
However, trends in deaths after release
from hospital gave no corresponding
indication that the programme had helped.
Together with the increase in total opioid-
related deaths in 2014 and 2015, it calls
into question whether overall the programme has had the desired effects, even if it further
reduced the small minority of deaths which occur after release from prison. Arguably, the
national programme was underpowered. During the years of the evaluation, it supplied only
about half the naloxone kits calculated as the target (8,000 a year) for a kit to be available
at every witnessed opiate overdose.
Wales
Wales’s national naloxone programme began in 2011 after an evaluation of pilot schemes.
These involved a single training session lasting one to two hours during which drug users
(and in a few cases their friends and family) were trained to recognise the signs of overdose
and how to respond with first aid and by administering naloxone, after which they were given
a naloxone kit. Since its piloting in 2009 and up the end of 2015/16, 10,552 naloxone kits
had been issued to 4,851 people, and 6,154 individuals had been trained in the
administration of naloxone and overdose prevention.
The programme has been gathering pace. The number of individuals newly supplied kits rose
24% to 1058 in 2015/16 and the number of kits issued either as first-time supply or as a
replacement rose 14% to 3,186. It has been calculated that for Wales the target for a kit to
be available at every witnessed opiate overdose is 1700 kits a year. From data gathered at
the time of resupply, kits were known to have been use 1,065 times, and more will have
been used without the carrier returning for another kit. Of the 1,065 known uses, just 11 or
about 1% were reported to have ended in a fatality. During 2015/16 a kit was known to have
been used in the attempt to save life at least once for every nine individuals registered as
carriers.
The programme has been linked to the decrease in drug misuse deaths in Wales, down by
17% from 162 in 2010 to 135 in both 2012 and 2013, but whether Wales’s programme really
had affected the death rate was unclear. Even in the absence of a national naloxone
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programme, from 2010 to 2012 drug misuse deaths also fell (by 14%) in England.
There they then rose steeply in 2013 to exceed the 2010 total while Wales sustained its
reduction, seen in an article titled “Bucking the trend” as a vindication of Wales’s
relative emphasis on harm reduction and de-emphasis on abstinence.
However, apparent success was to prove short-lived. The evidence had been a reduction
in deaths registered in Wales in 2014 compared to a rise in England, but in fact that
year there had also been a rise in Wales – in the number of deaths which actually
occurred during the year. The following year these fed through to registered deaths to
generate a sharp increase in 2015, a reversal which puzzled Public Health Wales.
Despite what may have turned out to be blip in the statistics, for its population of
problem drug users and of problem opioid users in particular, Wales’ death rates in 2015
were still lower than in England and Scotland. Authorities there remain convinced that
the naloxone programme is saving lives – “the single most effective intervention in the
prevention of drug related deaths”.
Northern Ireland
In 2012 distribution of naloxone kits and associated training were piloted in Northern
Ireland. Having planned to sample 40, evaluators were able to interview only 18 of the
362 opioid users at risk of overdose who by the end of August 2014 had been supplied a
kit. Most did not carry their kits with them because they were no longer in drug using
circles, or were concerned about stigma, harassment or legal/social consequences if
found with naloxone on their person. Distribution primarily through treatment services
both limited access and tended to confine it to opioid users in treatment.
Supported by the country’s Public Health Agency, the Council for the Homeless Northern
Ireland now offers naloxone training to homelessness, pharmacy, and addictions services
across Northern Ireland – “the first country globally to supply Naloxone to those at risk
of overdose on a countrywide basis”.
Naloxone programmes face inherent limitations
Even if naloxone programmes work as hoped, they will always be only a partial solution
to opioid overdose. They help prevent overdoses becoming fatal, while other
interventions such as treatment and transitioning injectors to less dangerous routes of
administration help prevent overdoses happening in the first place. In a context where
having a naloxone kit may be seen as marking one out as an active drug user and
offender, naloxone programmes are hampered by inherent limitations on the
preparedness of people to be trained and to carry the kits. They can only be used if they
are available at the right time and place, and if someone there is willing and able to use
them  more ...
Experts convened by the World Health Organization judged the “risk-benefit profile to be
strongly in favour of naloxone distribution, due to its clear potential for saving lives and
apparent low risk of significant adverse effects”, and strongly recommended naloxone
provision and associated training for people likely to witness an opioid overdose.
However, they also cautioned that this “does not address the underlying causes of opioid
overdose”; further reducing the number of deaths would also entail monitoring and
curbing inappropriate opioid prescribing and over-the-counter sales, and extending
treatment for opioid dependence. Wider initiatives of this kind were among those
recommended by Public Health England in its guidelines on preventing drug-related
deaths and by the US authorities in their Opioid overdose toolkit.
Using alone
One of the limitations of naloxone is that if deaths occur among isolated people in their
own homes, there is no one but the overdoser themselves to administer naloxone –
something they may be unable to do. Even if it has been issued to the drug user
concerned, this scenario (1 2) takes naloxone out of the equation and accounts for a
high proportion of deaths. In Scotland in 2014, where this information was available
only in 28% of incidents leading to a drug-related death was there another person in
the room. Such figures are expected because if the drug users were not alone, they
would have been less likely to die. Of more relevance is the proportion of opioid uses
which occur when the user is alone, making naloxone less likely to be administered. In
England for example, after release from prison about half the heroin users who returned
survey forms indicating that they had injected in the first two weeks also said they had
done so alone, and on average they had injected alone two-thirds of the time.
Issued but not available
Outside their homes, unless they are carrying naloxone with them, drug users issued
the kits will not be in a position to use them or have them used by others. In Northern
Ireland not having the kit with you was one of the reasons why it was not used in actual
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overdose incidents. In Scotland too, reluctance to carry the kits around may have
undermined the programme’s potential to save lives. Though some trainees kept their
kits with them all the time, others left it at home due to concerns that it would expose
them as a drug user if seen by the police, leading to detention and search and targeting
in future. A survey of needle exchange attendees in Scotland found that among the
minority who had injected in the past but not in the last six months, very few carried
the kits they had been given – in 2011–2012 just 5%, and in 2013–2014, just 1%, the
latter figure representing one person out of 81. But even among more recent injectors,
in 2013–2014 just 6% were carrying a kit when interviewed.
A trial in England of prison-release naloxone packaged the pre-filled syringe and related
information in a special wallet which also functions as a regular wallet – unobtrusive,
multi-use packaging which users may be more likely to take with them than a boxed
naloxone kit. Of 112 prisoners who completed follow-up surveys when reimprisoned
within six months, 71% said that in the first two weeks after release they had carried
the naloxone kit around with them, perhaps corresponding to the 69% who had
returned to heroin use during that period. Another 654 (ex-)prisoners had not returned
survey forms. How many also carried the drug around with them is unknown, as is
whether carriage was maintained beyond the first two weeks, but the results that are
known suggest high carriage rates can be engineered.
In Scotland in 2014, of the 34 cases where it was known that the deceased had been
issued a naloxone kit and also known whether it was available at the time of death, the
kit was used to try to save them in just 9 cases. Generally this was because only in 13
of the incidents was the naloxone available at the time, while in others it was available
but there was no other person around to administer it. These figures show deaths can
and do happen due to non-availability of issued kits, though many other deaths may
have been prevented by the kits being available.
Though universal carriage may be the ideal, in England in 2013 around 70% of
drug-related deaths occurred in the person’s home or at another private residential
address, such as a friend’s home. In Scotland in 2014, two-thirds of the people who died
a drug-related death had taken their drugs (67%) and died (63%) in their own homes.
In these circumstances, a naloxone kit may be present even if not carried about in
pockets or handbags.
If still aware enough, the person at risk may themselves refuse naloxone (1 2) for fear
of it precipitating withdrawal or because the effect of their expensive dose of heroin will
be nullified.
When it is administered, naloxone does not always prevent deaths. In Scotland in 2014,
of 21 deaths involving opioids where naloxone was known to be available, it was
administered in 18 cases. Why this failed to prevent the deaths is not known.
Another limitation is that for treatment services – especially those with a recovery
orientation – catering for the likelihood that their patients will not recover but relapse
to life-threatening opiate use may be a hard pill to swallow; swallowing it by training
clients and families to prepare for relapse may seem to counter-therapeutically
undermine the optimism at the heart of the recovery movement. Similarly, for patients
looking forward to a new life where they have escaped drugs and drugtaking circles,
learning a lifesaving technique predicated on continued contact with (largely) injecting
drug use(rs) can seem undermining and irrelevant.
More information
For more on the promise and limitations of naloxone see this analysis of a British study
of a naloxone training programme. Further guidance is available in the appendices to a
study conducted by the English National Treatment Agency for Substance Misuse. In
2008 staff from one of the English NHS trusts which piloted naloxone training for
families and carers produced a UK-focused practical guide to naloxone prescribing,
training and use. The Scottish Drugs Forum runs a web site offering naloxone-related
resources, advice, guidance, information and news. The organisation for GPs in Britain
with an interest in managing substance use problems runs a free online course on using
naloxone to prevent overdose. Under the banner of the Open Society Foundation, an
international collaboration has come together to offer advice and practical assistance on
starting a take-home naloxone programme. European Union guidance and information
on naloxone includes advice on setting up take-home naloxone training and distribution
programmes, and a European group of experts on drug-related deaths and their
prevention has contributed wide-ranging policy and practice advice on opioid overdose.
Guidance on overdose prevention in general with an emphasis on the role of naloxone
has also been produced by the Eurasian Harm Reduction Network. In the USA the
Chicago Recovery Alliance has produced a freely available training video. A video on
responding to an overdose and administering naloxone has also been made freely
available by the sudy in England of prison-release naloxone. The manufacturers of the
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naloxone preparation Prenoxad also offer advice on its use.
The many contributors to overdoses and possible strategies to prevent them were
reviewed by Findings in a two-part series and in another hot topic. Drug consumption
rooms are another way to prevent overdose deaths, the evidence for which and UK
policy were the subject of another hot topic. A further hot topic has discussed the
concept of harm reduction in general.
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